Skip to main content

Table 2 MBC/MFC in µg/ml of synthesized indole hybridized diazenyl derivatives (DS1–DS21)

From: Indole hybridized diazenyl derivatives: synthesis, antimicrobial activity, cytotoxicity evaluation and docking studies

Compound

E. coli

S. aureus

S. enterica

B. subtilis

K. pneumonia

A. niger

A. fumigatus

MBC/MFC (µg/ml)

 DS-1

125

125

62.5

125

7.81

125

125

 DS-2

16.25

125

15.62

125

62.5

125

62.5

 DS-3

31.25

62.5

31.25

62.5

31.25

125

62.5

 DS-5

31.25

125

62.5

125

15.62

125

125

 DS-6

3.90

31.25

31.25

62.5

7.81

125

125

 DS-7

31.25

125

31.25

125

16.25

125

125

 DS-10

31.25

125

62.5

125

7.81

125

125

 DS-11

62.5

62.5

125

125

31.25

125

125

 DS-13

3.90

62.5

62.5

125

15.62

125

125

 DS-14

7.81

62.5

7.81

62.5

3.90

125

125

 DS-15

125

31.25

31.25

62.5

31.25

125

125

 DS-16

62.5

125

62.5

125

31.25

125

125

 DS-17

15.62

62.5

62.5

62.5

15.62

125

125

 DS-19

62.5

31.25

62.5

125

15.62

125

125

 DS-20

7.81

62.5

31.25

125

15.62

125

125

 DS-21

7.81

62.5

31.25

62.5

7.81

125

125

 CFT

15.62

31.25

31.25

15.62

3.90

–

–

 CPR

31.25

62.5

31.25

31.25

7.81

–

–

 FLU

–

–

–

–

–

125

125

  1. CFT cefotaxime, CPR ciprofloxacin, FLU fluconazole